4-fluoro-N-(4-methoxyphenyl)benzothioamide | 102043-14-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-fluoro-N-(4-methoxyphenyl)benzothioamide
• 英文别名: N-4'-methoxyphenyl-4-fluorothiobenzamide；Hhogrjfiaqjvkj-uhfffaoysa-；4-fluoro-N-(4-methoxyphenyl)benzenecarbothioamide
• CAS: 102043-14-1
• 化学式: C₁₄H₁₂FNOS
• 分子量: 261.32
• InChiKey: HHOGRJFIAQJVKJ-UHFFFAOYSA-N

物化性质

• 熔点：
  159.2-159.6 °C(Solv: methanol (67-56-1))
• 沸点：
  365.3±52.0 °C(Predicted)
• 密度：
  1.278±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  53.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-fluoro-N-(4-methoxyphenyl)benzothioamide 在 potassium hexacyanoferrate(III) 、 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 2.0h， 以10%的产率得到6-methoxy-2-(4'-fluorophenyl)-1,3-benzothiazole
  参考文献：
  名称：

  Synthesis and Evaluation of ¹⁸F-Labeled 2-Phenylbenzothiazoles as Positron Emission Tomography Imaging Agents for Amyloid Plaques in Alzheimer’s Disease

  摘要：

  Imaging agents targeting amyloid beta(A beta) may be useful for early diagnosis and follow-up of treatment of patients with Alzheimer's disease (AD). Three of five tested 2-(4'-fluorophenyl)-1,3-benzothiazoles displayed high binding affinities for A beta plaques in AD human brain homogenates (K-i between 2.2 and 22.5 nM). They all contained the F-18-label directly attached to the aromatic ring and were synthesized starting from the nitro precursor. Determination of the partition coefficient, biodistribution studies in normal mice, and in vivo mu PET studies in normal rats showed that their initial brain uptake was high and brain washout was fast. The most promising compound [F-18]5, or 6- methyl-2-(4'-[F-18]fluorophenyl)-1,3-benzothiazole, seemed to be metabolically stable in the brain, and its plasma radiometabolites, which do not cross the blood-brain barrier, were determined. The preliminary results strongly suggest that this new fluorinated compound is a promising candidate as an A beta plaque imaging agent for the study of patients with AD.

  DOI：

  10.1021/jm8013376
• 作为产物：
  描述：

  4-氟-N-(4-甲氧基苯基)苯甲酰胺 在 劳森试剂 作用下， 以 1,4-二氧六环 为溶剂， 反应 3.0h， 以76%的产率得到4-fluoro-N-(4-methoxyphenyl)benzothioamide
  参考文献：
  名称：

  Synthesis and Evaluation of ¹⁸F-Labeled 2-Phenylbenzothiazoles as Positron Emission Tomography Imaging Agents for Amyloid Plaques in Alzheimer’s Disease

  摘要：

  Imaging agents targeting amyloid beta(A beta) may be useful for early diagnosis and follow-up of treatment of patients with Alzheimer's disease (AD). Three of five tested 2-(4'-fluorophenyl)-1,3-benzothiazoles displayed high binding affinities for A beta plaques in AD human brain homogenates (K-i between 2.2 and 22.5 nM). They all contained the F-18-label directly attached to the aromatic ring and were synthesized starting from the nitro precursor. Determination of the partition coefficient, biodistribution studies in normal mice, and in vivo mu PET studies in normal rats showed that their initial brain uptake was high and brain washout was fast. The most promising compound [F-18]5, or 6- methyl-2-(4'-[F-18]fluorophenyl)-1,3-benzothiazole, seemed to be metabolically stable in the brain, and its plasma radiometabolites, which do not cross the blood-brain barrier, were determined. The preliminary results strongly suggest that this new fluorinated compound is a promising candidate as an A beta plaque imaging agent for the study of patients with AD.

  DOI：

  10.1021/jm8013376

文献信息

• Base-Controlled Three Component Reactions of Amines, Elemental Sulfur, and Styrenes: Synthesis of Thioamides under Metal-Free Conditions
  作者：Pingshun Zhang、Wanzhi Chen、Miaochang Liu、Huayue Wu

  DOI：10.1021/acs.joc.8b01721

  日期：2018.12.7

  Three component reactions of olefins, amines, and sulfur were studied. Thioamidation of styrenes is base-controlled, and 2-phenylethanethioamides and benzothioamides were obtained selectively in the presence of two different bases. This protocol offers a simple and efficient procedure for the synthesis of thioamides.

  研究了烯烃，胺和硫的三组分反应。苯乙烯的硫酰胺化是碱控制的，并且在两种不同的碱的存在下选择性地获得了2-苯基乙硫酰胺和苯甲硫酰胺。该方案为合成硫酰胺提供了一种简单有效的方法。
• 一种硫代酰胺衍生物及其制备方法
  申请人：浙江大学

  公开号：CN108689895B

  公开（公告）日：2019-07-09

  本发明公开了一种硫代酰胺衍生物，其结构式如式(I)或式(II)所示；本发明还提供了所述硫代酰胺衍生物的制备方法，包括：以碱金属盐作为碱，将胺与烯烃和硫磺直接偶联，通过碱的选择，可用相同原料合成结构式如式(I)或式(II)所示的两种不同硫代酰胺衍生物。本发明提供的制备方法，其原料廉价易得，合成方法简单，可大大降低成本。本发明提供的硫代酰胺衍生物可应用于生物活性分子以及药物合成等领域，具有广泛的用途。
• Clemence; Joliveau-Maushart; Meier, European Journal of Medicinal Chemistry, 1985, vol. 20, # 3, p. 257 - 266
  作者：Clemence、Joliveau-Maushart、Meier、et al.

  DOI：——

  日期：——
• CLEMENCE, F.;JOLIVEAU-MAUSHART, C.;MEIER, J.;CEREDE, J.;DELEVALLEE, F.;BE+, EUR. J. MED. CHEM., 1985, 20, N 3, 257-266
  作者：CLEMENCE, F.、JOLIVEAU-MAUSHART, C.、MEIER, J.、CEREDE, J.、DELEVALLEE, F.、BE+

  DOI：——

  日期：——
• Synthesis and Evaluation of ¹⁸F-Labeled 2-Phenylbenzothiazoles as Positron Emission Tomography Imaging Agents for Amyloid Plaques in Alzheimer’s Disease
  作者：Kim Serdons、Christelle Terwinghe、Peter Vermaelen、Koen Van Laere、Hank Kung、Luc Mortelmans、Guy Bormans、Alfons Verbruggen

  DOI：10.1021/jm8013376

  日期：2009.3.12

  Imaging agents targeting amyloid beta(A beta) may be useful for early diagnosis and follow-up of treatment of patients with Alzheimer's disease (AD). Three of five tested 2-(4'-fluorophenyl)-1,3-benzothiazoles displayed high binding affinities for A beta plaques in AD human brain homogenates (K-i between 2.2 and 22.5 nM). They all contained the F-18-label directly attached to the aromatic ring and were synthesized starting from the nitro precursor. Determination of the partition coefficient, biodistribution studies in normal mice, and in vivo mu PET studies in normal rats showed that their initial brain uptake was high and brain washout was fast. The most promising compound [F-18]5, or 6- methyl-2-(4'-[F-18]fluorophenyl)-1,3-benzothiazole, seemed to be metabolically stable in the brain, and its plasma radiometabolites, which do not cross the blood-brain barrier, were determined. The preliminary results strongly suggest that this new fluorinated compound is a promising candidate as an A beta plaque imaging agent for the study of patients with AD.

表征谱图